Rutin.

Ascorbate reduces the flavonoid phenoxyl radical back to its active form, and the flavonoid in turn spares ascorbate from oxidation. The bioflavonoid plus ascorbate pairing dates to the original work on citrus flavonoids.

Rutin is quercetin carrying a rutinose sugar, and gut bacteria remove that sugar before the aglycone is absorbed. Rutin is effectively a slow-release, colon-delivered form of quercetin.

Rutin is poorly absorbed intact and depends on bacterial alpha-rhamnosidase and beta-glucosidase to release quercetin. The composition of the gut community determines how much is taken up.

Flavonoid aglycones are cleared rapidly by intestinal glucuronidation and sulfation, and piperine slows both. Circulating quercetin from rutin stays higher for longer.

Flavonoids reduce the tocopheroxyl radical back to tocopherol, returning it to the lipid phase where it works. The pairing is the standard aqueous and lipid phase division of labour.

Diosmin and rutin are both flavonoid glycosides used for capillary and venous wall tone, acting on endothelial permeability and venous smooth muscle. They are long-standing companions in venous formulas.

Escin acts on venous smooth muscle tone and capillary sealing through a saponin mechanism distinct from flavonoid antioxidant and permeability effects. The two are traditionally formulated together for that reason.

Ruscogenins act on adrenergic venous tone while flavonoids act on capillary permeability. The classic venous formula combines a ruscogenin source with rutin or a related flavonoid.

Polyphenols including rutin bind non-heme iron in the gut lumen through their catechol groups and hold it in a form the transporter cannot take up. Spacing the two apart by a couple of hours avoids the competition.

Quercetin, the aglycone released from rutin, moves zinc across lipid membranes as an ionophore. Intracellular zinc handling shifts when the two are taken together.

Rutin inhibits platelet protein disulfide isomerase and long chain omega-3 fatty acids shift eicosanoid balance away from thromboxane. Their effects on normal platelet aggregation are additive.

Ginkgolide B antagonises platelet activating factor while rutin acts on platelet thiol isomerase activity. Two separate points on platelet aggregation are affected at once.

Nattokinase has fibrinolytic activity and rutin acts on the platelet side of the same process. Combining them stacks two different steps of normal clot formation and breakdown.

Rutin and hesperidin are flavonoid glycosides that reach the colon largely intact and are deglycosylated by bacterial rhamnosidase and glucosidase activity. The resulting aglycones enter the same phase II conjugation route, so the pair loads one absorption and metabolism pathway rather than two. Formulators combine them for that reason. The pairing is formulation convention rather than a tested clinical combination.

Rutin is quercetin-3-O-rutinoside; removing the terminal rhamnose gives isoquercetin, the glucoside. The glucoside is taken up more readily at the small intestinal brush border, while the rutinoside depends on colonic bacteria to release its aglycone. Pairing the two spreads aglycone appearance across two different intestinal segments. This is settled flavonoid chemistry rather than a combination trial result.

Rutin is poorly absorbed as an intact diglycoside and depends on microbial enzymes to strip its sugars. Several Lactobacillus strains express the glycosidases that carry out that step in the colon. A person with low glycosidase-bearing flora releases less aglycone from the same rutin dose. The relationship is mechanistic; it has not been resolved as a clinical outcome.

Rutin needs colonic bacteria to reach its absorbable form. Inulin is fermented by bifidobacteria and lactobacilli and shifts the community that carries flavonoid glycosidase activity. The link between fibre intake and flavonoid aglycone release is an inference from microbial ecology, not from a paired human trial.

In a fermented pear juice model, pectin supplementation was reported to improve probiotic survival and preserve bioactive compounds, with rutin named among the compounds tracked. That is a food-matrix measurement, not a human absorption study. It suggests pectin can change how much rutin survives a fermented product, and nothing about what happens after ingestion.

Rutin binds divalent transition metals through its catechol and 4-keto-5-hydroxy sites. Taken in the same dose window as a copper supplement, it can form complexes that change how much free ion is available at the absorption site. Spacing the two apart avoids the interaction. This is chelation chemistry, not a measured deficit in people.

Manganese is a divalent cation with affinity for the catechol group rutin carries. Co-ingestion in the same window forms coordination complexes rather than free ion available for uptake. Separating the doses by a couple of hours removes the overlap. The direction is predicted by chemistry; the size of the effect in people has not been quantified.

Rutin quenches radicals and becomes an oxidised phenoxyl species; regeneration depends on cellular reductants. Alpha lipoic acid and its reduced form feed that pool. The two act at different points, one in the aqueous and membrane interface, the other across both compartments. Read this as mechanistic rather than clinical.

Animal work on rutin repeatedly reports glutathione status as the readout, which places rutin next to the cysteine supply chain rather than inside it. NAC supplies cysteine, the step that limits glutathione formation. The two support the same redox pool from different ends. Glutathione level is a marker, not an outcome.

Glutathione peroxidase is a selenoenzyme and cannot function without selenocysteine at its active site. Flavonoid supplementation that spares glutathione does nothing if the enzyme that uses it is short of selenium. The cofactor relationship is settled biochemistry. The joint effect on any clinical endpoint has not been tested.

Rutin aglycone and EGCG are both handled by sulfotransferases and UDP-glucuronosyltransferases in gut wall and liver. At high combined intakes the conjugating capacity is shared, which raises circulating unconjugated levels of whichever polyphenol is present in excess. That is a pharmacokinetic interaction, not a benefit or a harm on its own. Formulators who stack polyphenols should regard total polyphenol load as the relevant number.

Grape seed proanthocyanidins and rutin are both flavonoid-class polyphenols long combined in formulations aimed at supporting normal capillary structure. They differ in absorption: proanthocyanidin oligomers are poorly absorbed intact, rutin depends on colonic hydrolysis. The pairing is formulation practice with mechanistic overlap rather than a trialled combination.

Bromelain is routinely combined with rutin in flavonoid-enzyme formulations. The stated rationale is that proteolytic activity changes the intestinal environment in which the flavonoid is presented. Evidence for that specific step is thin. This is formulation practice, and the row is labelled accordingly.

Rosemary phenolics are lipid-phase antioxidants; rutin and its aglycone act more at aqueous and interfacial sites. Combining phenolics of different partition behaviour covers more of the membrane-to-cytosol gradient. The reasoning is chemical rather than clinical, and no combination trial anchors it.

Resveratrol is heavily sulfated on first pass, as is quercetin released from rutin. Co-ingestion at high doses puts two substrates into a finite sulfotransferase capacity, which changes each one's conjugate profile. Whether that raises or lowers useful exposure depends on dose and timing. Regard it as a kinetic interaction to account for, not an enhancement.